BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gasperi C, Stüve O, Hemmer B. B cell-directed therapies in multiple sclerosis. Neurodegenerative Disease Management 2016;6:37-47. [DOI: 10.2217/nmt.15.67] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmunity Reviews 2016;15:714-8. [DOI: 10.1016/j.autrev.2016.03.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
2 Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018;11:1756286418773025. [PMID: 29774057 DOI: 10.1177/1756286418773025] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
3 Ancau M, Berthele A, Hemmer B. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Expert Opinion on Biological Therapy 2019;19:829-43. [DOI: 10.1080/14712598.2019.1611778] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
4 Saadeh RS, Bryant SC, McKeon A, Weinshenker B, Murray DL, Pittock SJ, Willrich MAV. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clin Proc 2021:S0025-6196(21)00710-2. [PMID: 34893322 DOI: 10.1016/j.mayocp.2021.09.014] [Reference Citation Analysis]
5 Lechner P, Buck D, Sick L, Hemmer B, Multhoff G. Serum heat shock protein 70 levels as a biomarker for inflammatory processes in multiple sclerosis. Mult Scler J Exp Transl Clin 2018;4:2055217318767192. [PMID: 29780609 DOI: 10.1177/2055217318767192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Milo R; Department of Neurology, Barzilai University Medical Center, Ashkelon; Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel. Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis. European Neurological Review 2020;15:27. [DOI: 10.17925/enr.2020.15.1.27] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Nguyen AL, Gresle M, Marshall T, Butzkueven H, Field J. Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. Br J Pharmacol 2017;174:1895-907. [PMID: 28319650 DOI: 10.1111/bph.13780] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
8 Negron A, Robinson RR, Stüve O, Forsthuber TG. The role of B cells in multiple sclerosis: Current and future therapies. Cell Immunol 2019;339:10-23. [PMID: 31130183 DOI: 10.1016/j.cellimm.2018.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Mameli G, Cocco E, Frau J, Arru G, Caggiu E, Marrosu MG, Sechi LA. Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients. Sci Rep 2016;6:29268. [PMID: 27383531 DOI: 10.1038/srep29268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
10 Dubey D, Forsthuber T, Flanagan EP, Pittock SJ, Stüve O. B-cell-targeted therapies in relapsing forms of MS. Neurol Neuroimmunol Neuroinflamm 2017;4:e405. [PMID: 29082296 DOI: 10.1212/NXI.0000000000000405] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
11 Erdağ E, Şahin C, Küçükali Cİ, Bireller S, Küçükerden M, Kürtüncü M, Türkoğlu R, Cakmakoglu B, Tüzün E, Arıcıoğlu F. Effects of in vivo and in vitro administration of neuro-Behcet's disease IgG. Neurol Sci 2017;38:833-43. [PMID: 28224327 DOI: 10.1007/s10072-017-2856-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
12 Huang Q, Xiao B, Ma X, Qu M, Li Y, Nagarkatti P, Nagarkatti M, Zhou J. MicroRNAs associated with the pathogenesis of multiple sclerosis. Journal of Neuroimmunology 2016;295-296:148-61. [DOI: 10.1016/j.jneuroim.2016.04.014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
13 Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord 2017;10:51-66. [PMID: 28450895 DOI: 10.1177/1756285616666741] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
14 James ML, Hoehne A, Mayer AT, Lechtenberg K, Moreno M, Gowrishankar G, Ilovich O, Natarajan A, Johnson EM, Nguyen J, Quach L, Han M, Buckwalter M, Chandra S, Gambhir SS. Imaging B Cells in a Mouse Model of Multiple Sclerosis Using 64Cu-Rituximab PET. J Nucl Med 2017;58:1845-51. [PMID: 28687602 DOI: 10.2967/jnumed.117.189597] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
15 Knight A, Pauksens K, Nordmark G, Kumlien E. Fatal outcome of tick-borne encephalitis in two patients with rheumatic disease treated with rituximab. Rheumatology (Oxford) 2017;56:855-6. [PMID: 28130421 DOI: 10.1093/rheumatology/kew495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
16 Amato MP, Derfuss T, Hemmer B, Liblau R, Montalban X, Soelberg Sørensen P, Miller DH, Alfredsson L, Aloisi F, Amato MP, Ascherio A, Baldin E, Bjørnevik K, Comabella M, Correale J, Cortese M, Derfuss T, D’hooghe M, Ghezzi A, Gold J, Hellwig K, Hemmer B, Koch-henricksen N, Langer Gould A, Liblau R, Linker R, Lolli F, Lucas R, Lünemann J, Magyari M, Massacesi L, Miller A, Miller DH, Montalban X, Monteyne P, Mowry E, Münz C, Nielsen NM, Olsson T, Oreja-guevara C, Otero S, Pugliatti M, Reingold S, Riise T, Robertson N, Salvetti M, Sidhom Y, Smolders J, Soelberg Sørensen P, Sollid L, Steiner I, Stenager E, Sundstrom P, Taylor BV, Tremlett H, Trojano M, Uccelli A, Waubant E, Wekerle H; For the 2016 ECTRIMS Focused Workshop Group. Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Mult Scler 2018;24:590-603. [DOI: 10.1177/1352458516686847] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
17 Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L, Hauser S, Yamamoto Y, Wang Q, Model F, Kletzl H. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol 2021;87:2511-20. [PMID: 33202059 DOI: 10.1111/bcp.14658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Dormer L. Introducing a new volume of Neurodegenerative Disease Management. Neurodegener Dis Manag 2017;7:1-4. [PMID: 28128039 DOI: 10.2217/nmt-2016-0062] [Reference Citation Analysis]
19 Cheng Y, Sun L, Xie Z, Fan X, Cao Q, Han J, Zhu J, Jin T. Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. J Neurosci Res 2017;95:1973-83. [PMID: 28084640 DOI: 10.1002/jnr.24023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
20 Lee SK, Xing J, Catlett IM, Adamczyk R, Griffies A, Liu A, Murthy B, Nowak M. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants. Eur J Clin Pharmacol 2017;73:689-98. [PMID: 28265691 DOI: 10.1007/s00228-017-2226-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
21 Moritoki Y, Tsuneyama K, Nakamura Y, Kikuchi K, Shiota A, Ohsugi Y, Lian ZX, Zhang W, Yang GX, Ueki S, Takeda M, Omokawa A, Saga T, Saga A, Watanabe D, Miura M, Ueno Y, Leung PSC, Tanaka A, Gershwin ME, Hirokawa M. Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice. Front Immunol 2018;9:2534. [PMID: 30450101 DOI: 10.3389/fimmu.2018.02534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
22 Sundström P. Managing Epstein-Barr virus and other risk factors in MS-Future perspectives. Acta Neurol Scand 2017;136 Suppl 201:31-3. [PMID: 29068493 DOI: 10.1111/ane.12841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]